Edition:
United States

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

3.98USD
14 Dec 2017
Change (% chg)

$-0.21 (-5.01%)
Prev Close
$4.19
Open
$4.19
Day's High
$4.32
Day's Low
$3.97
Volume
40,936
Avg. Vol
138,905
52-wk High
$4.48
52-wk Low
$1.18

Select another date:

Tue, Nov 28 2017

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

BRIEF-Aptevo Therapeutics files mixed shelf of up to $150 mln

* Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2hvzJMI) Further company coverage:

BRIEF-Aptevo Therapeutics reports third quarter 2017 financial results

* Aptevo Therapeutics reports third quarter 2017 financial results

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - ‍ co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527​ Source text for Eikon: Further company coverage:

BRIEF-APTEVO THERAPEUTICS ‍AMENDS TERMS OF CREDIT AGREEMENT

* APTEVO THERAPEUTICS INC - ‍AMENDED TERMS OF A CREDIT AGREEMENT INITIALLY EXECUTED WITH MIDCAP FINANCIAL TRUST IN AUGUST 2016​

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414

* Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414

BRIEF-Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products

* Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products

BRIEF-Aptevo and Alligator Bioscience start IND-enabling development activities immunotherapy drug

* Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

BRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement

* Aptevo Therapeutics- on June 17, unit and CMC ICOS biologics entered non-exclusive amended and restated commercial supply agreement - SEC filing

Select another date: